Also known as: GLP-1 agonists, Incretin agonists, Weight loss medications
GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide) are the dominant new drug class for weight management and type 2 diabetes. They all work the same way: activating incretin receptors slows gastric emptying, increases satiety, and improves insulin response. Two SNPs explain a lot of the variation between patients. GLP1R rs10305420 affects every drug in the class. GIPR rs1800437 only matters for drugs that also activate GIP, which is tirzepatide and retatrutide.
Each link goes to the drug's full pharmacogenetics page with CPIC and FDA phenotype recommendations.
Combined products and brand names for the medications above. Each links to a pharmacogenetic breakdown.
This page covers the pharmacogenetics of weight management (glp-1 agonists) in general. A Gene2Rx report tells you how your personal genotype interacts with every drug on this page.
Get your report Look up a medicationInformational only, not medical advice. Pharmacogenetic guidelines describe population-level patterns that inform prescribing decisions. Never start, stop, or change a medication without talking to your prescribing clinician.